SeekingAlphaOctober 14, 2026 at 5:38 AM NY13 Days Ago
AI Disruption May Benefit Cencora More Than Hims & Hers
Cencora (COR) may gain from AI-driven prescribing volume growth; with strong operating leverage and discounted P/E, see risks and $365 targetâread now.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: SeekingAlpha
